Recently I began coverage of Seattle Genetics (NASDAQ:SGEN) with the expectation it will outperform the broad market. The company's share price took a hit following positive data presented at a recent conference. I expect label expansion opportunities for the company's commercial stage asset, Adcetris to drive growth in the near term. Looking further ahead the company has several promising candidates in early-stage development, and a slew of collaboration agreements.
Seattle Genetics has the industry's leading antibody drug conjugate platform. This technology improves patient outcomes through the targeted delivery cytotoxic agents to the interior of tumor cells. Because the company's ADC technology is so widely applicable, industry heavyweights have beaten a path to the company's door. As the company transitions to the next phase of its growth story, it should enjoy a significant stream of milestone and royalty revenues from an enviable number of partnerships with industry giants.
Read the complete post at Seeking Alpha, here's the link.